The development of CAR T cells currently represents an exciting opportunity to convert the already published clinical successes observed in clinical trials into commercially available efficient therapies. However, the path toward successful commercialization is still hindered by many hurdles. Here, we review such issues as: the need for structured collaborations between hospital collection and clinical facilities and industry manufacturing facilities to streamline the supply chain; necessity for uniform and efficient medical procedures to cope with severe toxicities associated with CAR T cells; and absolute need to define an economical and sustainable model for manufacturers and payers. The fast pace at which the field is evolving requires careful assessments for the benefit of patients.

CAR T细胞的发展目前代表着一个令人兴奋的机会，它将在临床试验中观察到的已经发表的临床成功转化为可商购的有效疗法。但是，成功实现商业化的道路仍然受到许多障碍的阻碍。在这里，我们回顾以下问题：医院收集，临床设施和行业制造设施之间需要进行结构化协作以简化供应链；必须采取统一和有效的医疗程序来应对与CAR T细胞相关的严重毒性；绝对需要为制造商和付款方定义一种经济且可持续的模型。该领域的快速发展需要对患者的利益进行认真评估。